126 related articles for article (PubMed ID: 3948164)
21. Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists.
Griswold DE; Alessi S; Badger AM; Poste G; Hanna N
J Immunol; 1984 Jun; 132(6):3054-7. PubMed ID: 6202771
[TBL] [Abstract][Full Text] [Related]
22. Effects of cimetidine or ranitidine on the pharmacokinetics of flurbiprofen.
Sullivan KM; Small RE; Rock WL; Cox SR; Willis HE
Clin Pharm; 1986 Jul; 5(7):586-9. PubMed ID: 3742949
[TBL] [Abstract][Full Text] [Related]
23. Cimetidine and ranitidine. Lack of effect on the pharmacokinetics of an acute ethanol dose.
Dauncey H; Chesher GB; Palmer RH
J Clin Gastroenterol; 1993 Oct; 17(3):189-94. PubMed ID: 8228077
[TBL] [Abstract][Full Text] [Related]
24. Protection by cimetidine, but not ranitidine, implies that H2 receptors do not mediate arrhythmogenesis in a rat model of regional ischaemia and reperfusion in vitro.
Banning MM; Curtis MJ
Cardiovasc Res; 1995 Nov; 30(5):705-10. PubMed ID: 8595616
[TBL] [Abstract][Full Text] [Related]
25. [H2 histamine antagonists and the hypothalamo-hypophyseal-gonadal axis: effect of short-term treatment on serum levels of prolactin, FSH, LH and testosterone in male ulcer patients].
Biagi P; Galli M; Brettoni A; Rizzo AA; Massafra C
Quad Sclavo Diagn; 1983 Sep; 19(3):313-21. PubMed ID: 6146158
[TBL] [Abstract][Full Text] [Related]
26. Effect of H2-receptor antagonists on the pharmacokinetics of 5-fluorouracil in the rat and monkey.
Dilloway MR; Lant AF
Biopharm Drug Dispos; 1991; 12(1):17-28. PubMed ID: 1674889
[TBL] [Abstract][Full Text] [Related]
27. Protective effect of triterpenoid fractions from the rhizomes of Astilbe chinensis on cyclophosphamide-induced toxicity in tumor-bearing mice.
Sun HX; Peng XY
J Ethnopharmacol; 2008 Sep; 119(2):312-7. PubMed ID: 18692125
[TBL] [Abstract][Full Text] [Related]
28. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
29. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
Emmenegger U; Man S; Shaked Y; Francia G; Wong JW; Hicklin DJ; Kerbel RS
Cancer Res; 2004 Jun; 64(11):3994-4000. PubMed ID: 15173013
[TBL] [Abstract][Full Text] [Related]
30. The pharmacokinetics of H2 receptor blocking agents in compensated liver cirrhosis.
Okolicsányi L; Venuti M; Strazzabosco M; Iemmolo RM; Nassuato G; Orlando R; Lirussi F
Acta Physiol Hung; 1984; 64(3-4):393-400. PubMed ID: 6099684
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of tolbutamide elimination by cimetidine but not ranitidine.
Cate EW; Rogers JF; Powell JR
J Clin Pharmacol; 1986; 26(5):372-7. PubMed ID: 3700691
[TBL] [Abstract][Full Text] [Related]
32. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
Góra-Tybor J; Robak T
Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
[TBL] [Abstract][Full Text] [Related]
33. Effects of cimetidine and ranitidine on trimethadione metabolism in the rat.
Tanaka E; Misawa S
Res Commun Chem Pathol Pharmacol; 1985 Mar; 47(3):461-4. PubMed ID: 3992022
[TBL] [Abstract][Full Text] [Related]
34. Neuromuscular blocking drug pharmacodynamics after chronic exposure to H2- antagonists.
Rana J; Ramzan I
In Vivo; 1995; 9(2):163-6. PubMed ID: 7548793
[TBL] [Abstract][Full Text] [Related]
35. Potentiation of the activity of cisplatin and cyclophosphamide by trimidox, a novel ribonucleotide reductase inhibitor, in leukemia-bearing mice.
Novotny L; Rauko P; Liska J; Elford HL; Szekeres T
Cancer Lett; 2006 Feb; 233(1):178-84. PubMed ID: 15885888
[TBL] [Abstract][Full Text] [Related]
36. Hematoporphyrin derivative rescue from toxicity caused by chemotherapy or radiation in a murine leukemia model (L1210).
Canti G; Franco P; Marelli O; Ricci L; Nicolin A
Cancer Res; 1984 Apr; 44(4):1551-6. PubMed ID: 6231100
[TBL] [Abstract][Full Text] [Related]
37. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
Wang X; Zhang J; Xu T
Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
[TBL] [Abstract][Full Text] [Related]
38. Effects of cimetidine and ranitidine on the pharmacokinetics of quinine.
Wanwimolruk S; Sunbhanich M; Pongmarutai M; Patamasucon P
Br J Clin Pharmacol; 1986 Sep; 22(3):346-50. PubMed ID: 3768247
[TBL] [Abstract][Full Text] [Related]
39. The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans.
Vree TB; van den Biggelaar-Martea M; Verwey-van Wissen CP; Vree ML; Guelen PJ
Int J Clin Pharmacol Ther Toxicol; 1993 Dec; 31(12):597-601. PubMed ID: 8314361
[TBL] [Abstract][Full Text] [Related]
40. [The effects of histamine H2 receptor agonist, antagonist and antineoplastic agent on the in vitro growth of PB CFU-GM from normal individuals and HL-60 leukemia cells].
He Q; Xu YH
Yao Xue Xue Bao; 1996; 31(5):340-5. PubMed ID: 9275711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
